317335-26-5 Usage
Description
N-METHOXY-N-METHYL-PYRAZINE-2-CARBOXAMIDE is an organic compound that serves as a key intermediate in the synthesis of various chemical compounds. It is characterized by its unique molecular structure, which allows it to participate in a range of chemical reactions and contribute to the formation of different products.
Uses
Used in Pharmaceutical Industry:
N-METHOXY-N-METHYL-PYRAZINE-2-CARBOXAMIDE is used as a synthetic intermediate for the production of aryl/heteroaryl Weinreb amides through Pd-catalyzed aminocarbonylation. This application is significant because Weinreb amides are versatile reagents in organic synthesis, particularly in the preparation of esters, ketones, and other valuable compounds. The use of N-METHOXY-N-METHYL-PYRAZINE-2-CARBOXAMIDE in this process enables the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, N-METHOXY-N-METHYL-PYRAZINE-2-CARBOXAMIDE is utilized as a building block for the synthesis of complex organic molecules. Its unique properties and reactivity make it a valuable tool for chemists working on the development of new materials, catalysts, and other specialty chemicals. By incorporating this compound into their research, scientists can explore new reaction pathways and create novel molecules with potential applications in various industries.
Used in Material Science:
N-METHOXY-N-METHYL-PYRAZINE-2-CARBOXAMIDE can also be employed in the development of new materials with specific properties. For instance, it may be used to synthesize compounds with unique optical, electronic, or mechanical characteristics, which could be applied in the creation of advanced materials for various applications, such as electronics, sensors, or coatings.
Check Digit Verification of cas no
The CAS Registry Mumber 317335-26-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,7,3,3 and 5 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 317335-26:
(8*3)+(7*1)+(6*7)+(5*3)+(4*3)+(3*5)+(2*2)+(1*6)=125
125 % 10 = 5
So 317335-26-5 is a valid CAS Registry Number.
317335-26-5Relevant articles and documents
Benzoheterocyclic Oxime Carbamates Active against Mycobacterium tuberculosis: Synthesis, Structure-Activity Relationship, Metabolism, and Biology Triaging
Van Der Westhuyzen, Renier,Mabhula, Amanda,Njaria, Paul M.,Müller, Rudolf,Ngumbu Muhunga, Denis,Taylor, Dale,Lawrence, Nina,Njoroge, Mathew,Brunschwig, Christel,Moosa, Atica,Singh, Vinayak,Rao, Srinivasa P.S.,Manjunatha, Ujjini H.,Smith, Paul W.,Warner, Digby F.,Street, Leslie J.,Chibale, Kelly
supporting information, p. 9444 - 9457 (2021/07/19)
Screening of a library of small polar molecules against Mycobacterium tuberculosis (Mtb) led to the identification of a potent benzoheterocyclic oxime carbamate hit series. This series was subjected to medicinal chemistry progression underpinned by structure-activity relationship studies toward identifying a compound for proof-of-concept studies and defining a lead optimization strategy. Carbamate and free oxime frontrunner compounds with good stability in liver microsomes and no hERG channel inhibition liability were identified and evaluated in vivo for pharmacokinetic properties. Mtb-mediated permeation and metabolism studies revealed that the carbamates were acting as prodrugs. Toward mechanism of action elucidation, selected compounds were tested in biology triage assays to assess their activity against known promiscuous targets. Taken together, these data suggest a novel yet unknown mode of action for these antitubercular hits.
HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
-
Paragraph 0342; 0343; 0350; 0351, (2014/05/07)
The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
